Adjuvant

16 drugs in development·14 companies·2 clinical trials

Drug Pipeline by Phase

Approved(9)

Drug	Company
ABRAXANE	ImmunityBio, Inc. (IBRX)
docetaxel	Amneal Pharmaceuticals, Inc. (AMRX)
doxorubicin	Amneal Pharmaceuticals, Inc. (AMRX)
eribulin	DR REDDYS LABORATORIES LTD (RDY)
ibrance	PFIZER INC (PFE)
kisqali femara co-pack	Novartis AG (NVS)
ogivri	Mylan II B.V. (MYL)
opdivo qvantig	BRISTOL MYERS SQUIBB CO (BMY)
paclitaxel	Mylan II B.V. (MYL)

Phase 3(4)

Drug	Company
A10 and AS2-1 Antineoplaston	BURZYNSKI RESEARCH INSTITUTE INC (BZYR)
Multikine	CEL SCI CORP (CVM)
sacituzumab govitecan	Phoenix Life Sciences International Limited. (PLSI)
seviprotimut-l	Transcode Therapeutics, Inc. (RNAZ)

Phase 2(1)

Drug	Company
Toripalimab	Filana Therapeutics Inc. (FLNA)

Phase 1/Phase 2(1)

Drug	Company
eli-004	Elicio Therapeutics, Inc. (ELTX)

Phase 4(1)

Drug	Company
Individualized neoantigen therapy	Moderna, Inc. (MRNA)

BioSniper tracks 16 drugs in development for Adjuvant across 14 companies.

There are 2 clinical trials targeting Adjuvant tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.